Nargenicin
| Code | Size | Price |
|---|
| TAR-T36417-1mg | 1mg | £311.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T36417-5mg | 5mg | £799.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Nargenicin is a macrolide antibiotic that selectively inhibits the growth of S. aureus, methicilin resistant S. aureus (MRSA), and M. luteus (MICs = 0.6, 0.3, and 2.5 μg/ml, respectively) over a panel of 11 Gram-positive and Gram-negative bacteria (MICs = >80 μg/ml). [1] It dose-dependently inhibits S. aureus DnaE in the presence of DNase I-activated DNA and E. coli DnaE when used at concentrations of 0.00001-0.1 and 0.01-100 μg/mL, respectively. [2] In murine BV-2 microglial cells, nargenicin (1 μM) inhibits cytokine expression and nitric oxide production induced by LPS.[3] Nargenicin (200 μM), when used in combination with 1,25-dihydroxyvitamin D3 or all-trans retinoic acid , reduces cell proliferation by 37-47% and increases cell differentiation by 82-85% in HL-60 human myeloid leukemia cells.[4]
CAS:
70695-02-2
Formula:
C28H37NO8
Molecular Weight:
515.603
Purity:
0.98
SMILES:
[H][C@]12C=C[C@]3([H])C[C@H](OC)C(=O)O[C@]([H])([C@@H](C)O)[C@H](C)C=C(C)[C@]33O[C@H]1[C@H](OC(=O)c1ccc[nH]1)[C@H](C)[C@@H](O)[C@]23[H]
References
Kim, S.H., Yoo, J.C., and Kim, T.S. Nargenicin enhances 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced leukemia cell differentiation via PKC?I/MAPK pathways. Biochem. Pharmacol. 77(11), 1694-1701 (2009).
Yoo, J.C., Cho, H.S., Park, E., et al. Nargenicin attenuates lipopolysaccharide-induced inflammatory responses in BV-2 cells. Neuroreport 20(11), 1007-1012 (2009).
Painter, R.E., Adam, G.C., Arocho, M., et al. Elucidation of DnaE as the antibacterial target of the natural product, nargenicin. Chem. Biol. 22(10), 1362-1373 (2015).
Sohng, J.K., Yamaguchi, T., Seong, C.N., et al. Production, isolation and biological activity of nargenicin from Nocardia sp. CS682. Arch. Pharm. Res. 31(10), 1339-1345 (2008).